EP4031122A4 - Effervescent tablet formulations comprising dapagliflozin and metformin - Google Patents

Effervescent tablet formulations comprising dapagliflozin and metformin Download PDF

Info

Publication number
EP4031122A4
EP4031122A4 EP20866500.0A EP20866500A EP4031122A4 EP 4031122 A4 EP4031122 A4 EP 4031122A4 EP 20866500 A EP20866500 A EP 20866500A EP 4031122 A4 EP4031122 A4 EP 4031122A4
Authority
EP
European Patent Office
Prior art keywords
dapagliflozin
metformin
effervescent tablet
tablet formulations
formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20866500.0A
Other languages
German (de)
French (fr)
Other versions
EP4031122A1 (en
Inventor
Abdullah TASKIN
Yavuz Dedeoglu
Muge ULUSOY BOZYEL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanovel Ilac Sanayi ve Ticaret AS
Original Assignee
Sanovel Ilac Sanayi ve Ticaret AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanovel Ilac Sanayi ve Ticaret AS filed Critical Sanovel Ilac Sanayi ve Ticaret AS
Publication of EP4031122A1 publication Critical patent/EP4031122A1/en
Publication of EP4031122A4 publication Critical patent/EP4031122A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
EP20866500.0A 2019-09-16 2020-08-05 Effervescent tablet formulations comprising dapagliflozin and metformin Pending EP4031122A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2019/14043A TR201914043A1 (en) 2019-09-16 2019-09-16 EFERVESAN TABLET FORMULATIONS CONTAINING DAPAGLYFLOZIN AND METFORMIN
PCT/TR2020/050687 WO2021054912A1 (en) 2019-09-16 2020-08-05 Effervescent tablet formulations comprising dapagliflozin and metformin

Publications (2)

Publication Number Publication Date
EP4031122A1 EP4031122A1 (en) 2022-07-27
EP4031122A4 true EP4031122A4 (en) 2023-08-30

Family

ID=74883168

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20866500.0A Pending EP4031122A4 (en) 2019-09-16 2020-08-05 Effervescent tablet formulations comprising dapagliflozin and metformin

Country Status (3)

Country Link
EP (1) EP4031122A4 (en)
TR (1) TR201914043A1 (en)
WO (1) WO2021054912A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4079296A1 (en) * 2021-04-21 2022-10-26 Sanovel Ilac Sanayi Ve Ticaret A.S. A bilayer tablet formulation comprising amorphous dapagliflozin and metformin

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150238421A1 (en) * 2009-11-13 2015-08-27 Astrazeneca Ab Bilayer Tablet Formulations
WO2017098481A1 (en) * 2015-12-12 2017-06-15 Steerlife India Private Limited Effervescent compositions of metformin and processes for preparation thereof
WO2018185669A1 (en) * 2017-04-07 2018-10-11 Zenvision Pharma Llp Effervescent compositions comprising saxagliptin or salt thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007038979A1 (en) * 2005-09-22 2007-04-12 Swissco Development Ag Effervescent metformin composition and tablets and granules made therefrom
EP2809311A1 (en) * 2012-01-31 2014-12-10 Mahmut Bilgic Effervescent tablet formulations comprising the combination of voglibose and metformin

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150238421A1 (en) * 2009-11-13 2015-08-27 Astrazeneca Ab Bilayer Tablet Formulations
WO2017098481A1 (en) * 2015-12-12 2017-06-15 Steerlife India Private Limited Effervescent compositions of metformin and processes for preparation thereof
WO2018185669A1 (en) * 2017-04-07 2018-10-11 Zenvision Pharma Llp Effervescent compositions comprising saxagliptin or salt thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2021054912A1 *

Also Published As

Publication number Publication date
TR201914043A1 (en) 2021-04-21
WO2021054912A1 (en) 2021-03-25
EP4031122A1 (en) 2022-07-27

Similar Documents

Publication Publication Date Title
EP4051246A4 (en) Bilayer tablet formulations comprising dapagliflozin and metformin
IL284835A (en) Pharmaceutical combination comprising tno155 and ribociclib
EP4045480A4 (en) Pharmaceutical formulations
EP3706741A4 (en) Pharmaceutical composition and use thereof
EP3938369A4 (en) Tyk2 inhibitors and uses thereof
EP3914357A4 (en) Tyk2 inhibitors and uses thereof
EP3904351A4 (en) Fak inhibitor and drug combination thereof
EP3981769A4 (en) Pyrrolopyrimidine compound and use thereof
EP3851121A4 (en) Human anti-il-33 monoclonal-antibody-containing pharmaceutical composition
EP3999183A4 (en) Compound having kdm5 inhibitory activity and pharmaceutical use thereof
EP3784672A4 (en) Tablet formulations comprising metformin and sitagliptin
EP3919498A4 (en) Pyrrolopyrimidine derivative and use thereof
EP3976014A4 (en) A combination comprising alogliptin and metformin
EP4031122A4 (en) Effervescent tablet formulations comprising dapagliflozin and metformin
EP4112047A4 (en) Oral complex tablet comprising sitagliptin, dapagliflozin, and metformin
EP3999056A4 (en) Pharmaceutical combination and use thereof
EP4014999A4 (en) Combination product containing limonin compound and sulfonylurea drug
EP4048276A4 (en) Solid pharmaceutical formulations comprising ticagrelor
EP3962528A4 (en) Therapeutic combinations comprising anti-cd123 immunoconjugates
EP4058025A4 (en) Pharmaceutical compositions comprising ticagrelor
EP3694519A4 (en) The pharmaceutical combination comprising dapoxetine and phosphodiesterase type-5
EP3746080A4 (en) Pharmaceutical formulations
EP3664800A4 (en) Therapeutic formulations and uses thereof
AU2022306548A1 (en) Oral complex tablet comprising sitagliptin, dapagliflozin, and metformin
EP4041245A4 (en) Therapeutic formulations and uses thereof

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220315

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230708

A4 Supplementary search report drawn up and despatched

Effective date: 20230727

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 3/10 20060101ALI20230721BHEP

Ipc: A61K 9/20 20060101ALI20230721BHEP

Ipc: A61K 31/351 20060101ALI20230721BHEP

Ipc: A61K 31/155 20060101AFI20230721BHEP